MA39833A - Nouvelle utilisation du n,n-bis-2-mercaptoéthyl isophtalamide - Google Patents

Nouvelle utilisation du n,n-bis-2-mercaptoéthyl isophtalamide

Info

Publication number
MA39833A
MA39833A MA039833A MA39833A MA39833A MA 39833 A MA39833 A MA 39833A MA 039833 A MA039833 A MA 039833A MA 39833 A MA39833 A MA 39833A MA 39833 A MA39833 A MA 39833A
Authority
MA
Morocco
Prior art keywords
bis
mercaptoethyl
isophtalamide
new use
startfragment
Prior art date
Application number
MA039833A
Other languages
English (en)
Other versions
MA39833B1 (fr
Inventor
Boyd Eugene Haley
Ragnar Axel Theodor Klingberg
Original Assignee
Emeramed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50776843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39833(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Emeramed Ltd filed Critical Emeramed Ltd
Publication of MA39833A publication Critical patent/MA39833A/fr
Publication of MA39833B1 publication Critical patent/MA39833B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

<!--startfragment-->la présente invention concerne le n,n-bis-2-mercaptoéthyl isophtalamide, ou un sel ou dérivé pharmaceutiquement acceptable dudit composé, destiné à être utilisé pour la régénération systémique d'ascorbate, et donc dans le traitement thérapeutique de la bronchopneumopathie chronique obstructive<!--endfragment-->
MA39833A 2014-04-04 2015-03-31 Nouvelle utilisation du n,n-bis-2-mercaptoéthyl isophtalamide MA39833B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1406115.4A GB2524831A (en) 2014-04-04 2014-04-04 New pharmaceutical use
PCT/GB2015/050999 WO2015150793A1 (fr) 2014-04-04 2015-03-31 Nouvelle utilisation du n,n-bis-2-mercaptoéthyl isophtalamide

Publications (2)

Publication Number Publication Date
MA39833A true MA39833A (fr) 2017-02-08
MA39833B1 MA39833B1 (fr) 2018-04-30

Family

ID=50776843

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39833A MA39833B1 (fr) 2014-04-04 2015-03-31 Nouvelle utilisation du n,n-bis-2-mercaptoéthyl isophtalamide

Country Status (36)

Country Link
US (1) US9782368B2 (fr)
EP (1) EP3125876B8 (fr)
JP (1) JP6474423B2 (fr)
KR (1) KR102482699B1 (fr)
CN (1) CN106132405B (fr)
AU (1) AU2015242374B2 (fr)
BR (1) BR112016022880B1 (fr)
CA (1) CA2944113C (fr)
CL (1) CL2016002499A1 (fr)
CY (1) CY1121235T1 (fr)
DK (1) DK3125876T3 (fr)
EA (1) EA032116B1 (fr)
EC (1) ECSP16078100A (fr)
ES (1) ES2659174T3 (fr)
GB (1) GB2524831A (fr)
HR (1) HRP20180325T1 (fr)
HU (1) HUE036206T2 (fr)
IL (1) IL248027B (fr)
LT (1) LT3125876T (fr)
MA (1) MA39833B1 (fr)
ME (1) ME03012B (fr)
MX (1) MX2016012591A (fr)
NO (1) NO3125876T3 (fr)
NZ (1) NZ724678A (fr)
PE (1) PE20170586A1 (fr)
PH (1) PH12016501975A1 (fr)
PL (1) PL3125876T3 (fr)
PT (1) PT3125876T (fr)
RS (1) RS56905B1 (fr)
SA (1) SA516371966B1 (fr)
SG (1) SG11201607478RA (fr)
SI (1) SI3125876T1 (fr)
SM (1) SMT201800116T1 (fr)
UA (1) UA119558C2 (fr)
WO (1) WO2015150793A1 (fr)
ZA (1) ZA201606406B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202005057D0 (en) 2020-04-06 2020-05-20 Emeramed Ltd New Use
CN114778234B (zh) * 2022-03-18 2025-08-15 武汉新烽光电股份有限公司 一种用于微流控总磷测试的抗坏血酸溶液的保存方法及保存结构
WO2026037909A1 (fr) * 2024-08-16 2026-02-19 Emeramed Limited N,n-bis-2-mercaptoéthyl isophtalamide destiné à être utilisé dans le traitement de la douleur

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586600B2 (en) 2000-12-06 2003-07-01 University Of Kentucky Research Foundation Multidentate sulfur-containing ligands
JP2011026204A (ja) * 2007-11-26 2011-02-10 Rei Furukawa タバコの煙を吸入することにより引き起こされる疾患の予防及び／又は治療用組成物
US8950583B2 (en) * 2008-12-06 2015-02-10 Ermes Medical Company Limited Method to remove heavy metals from a mammal
US8575218B2 (en) 2009-09-28 2013-11-05 The University Of Kentucky Research Foundation Thiol-containing compounds for the removal of elements from tissues and formulations therefor
CA2775397A1 (fr) 2009-09-28 2011-03-31 University Of Kentucky Research Foundation Composes contenant un thiol pour l'elimination d'elements de milieux contamines et procedes d'utilisation associes
US20110237776A1 (en) 2010-03-25 2011-09-29 Haley Boyd E Aromatic compounds with sulfur containing ligands
US8426368B2 (en) * 2010-03-25 2013-04-23 The University Of Kentucky Research Foundation Method of ameliorating oxidative stress and supplementing the diet

Also Published As

Publication number Publication date
HUE036206T2 (hu) 2018-06-28
EA032116B1 (ru) 2019-04-30
US9782368B2 (en) 2017-10-10
GB201406115D0 (en) 2014-05-21
ME03012B (fr) 2018-10-20
JP2017511307A (ja) 2017-04-20
PL3125876T3 (pl) 2018-05-30
NO3125876T3 (fr) 2018-04-28
SG11201607478RA (en) 2016-10-28
PE20170586A1 (es) 2017-05-20
KR20160140929A (ko) 2016-12-07
CL2016002499A1 (es) 2017-01-27
CA2944113A1 (fr) 2015-10-08
RS56905B1 (sr) 2018-05-31
AU2015242374B2 (en) 2019-10-10
UA119558C2 (uk) 2019-07-10
CA2944113C (fr) 2022-06-21
GB2524831A (en) 2015-10-07
EA201692013A1 (ru) 2017-03-31
CN106132405A (zh) 2016-11-16
BR112016022880B1 (pt) 2022-09-13
EP3125876A1 (fr) 2017-02-08
BR112016022880A2 (fr) 2017-08-15
ES2659174T3 (es) 2018-03-14
KR102482699B1 (ko) 2022-12-28
SA516371966B1 (ar) 2019-04-14
SI3125876T1 (en) 2018-04-30
DK3125876T3 (en) 2018-01-15
JP6474423B2 (ja) 2019-02-27
LT3125876T (lt) 2018-02-12
IL248027B (en) 2019-03-31
PT3125876T (pt) 2018-02-22
SMT201800116T1 (it) 2018-03-08
EP3125876B8 (fr) 2018-01-24
US20170157072A1 (en) 2017-06-08
MA39833B1 (fr) 2018-04-30
CN106132405B (zh) 2019-06-18
MX2016012591A (es) 2017-04-06
ZA201606406B (en) 2018-04-25
CY1121235T1 (el) 2020-05-29
PH12016501975A1 (en) 2017-01-09
NZ724678A (en) 2022-12-23
AU2015242374A1 (en) 2016-10-13
HRP20180325T1 (hr) 2018-04-06
EP3125876B1 (fr) 2017-11-29
ECSP16078100A (es) 2018-03-31
WO2015150793A1 (fr) 2015-10-08

Similar Documents

Publication Publication Date Title
ME03314B (fr) Thérapie basée sur l&#39;arnm pour le traitement des maladies oculaires
EP3019491A4 (fr) Inhibiteurs de kinase pour le traitement d&#39;une maladie
FR3046933B1 (fr) Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
EP3558313A4 (fr) Substances pour le traitement d&#39;affections liées à la stéatose hépatique
EP3013345A4 (fr) Composés pour le traitement d&#39;une amyotrophie spinale
MA49760A (fr) Mavacamten destiné à être utilisé dans le traitement de la cardiomyopathie hypertrophique
EA201790528A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
EP3731847A4 (fr) Administration pulsée d&#39;oxyde nitrique inhalé pour le traitement de l&#39;hypertension pulmonaire
EP3630964A4 (fr) Agents thérapeutiques pour la maladie du stockage du glycogène de type iii
MX375902B (es) Inhibidores de serina/treonina cinasa.
EP3901138A4 (fr) Composé destiné à être utilisé dans des maladies rétiniennes
EP2709453A4 (fr) Utilisation de composés thiazolides pour la prévention et le traitement d&#39;infections virales, du cancer et de maladies causées par des infections intracellulaires
EP2970099A4 (fr) Dérivés de 3-phénylpropylamine substitués pour le traitement des maladies et des troubles ophtalmiques
PL3405215T3 (pl) Sposoby leczenia choroby danona i innych zaburzeń autofagii
EP3763815A4 (fr) Agent thérapeutique pour la maladie du stockage du glycogène de type ia
HUE060496T2 (hu) Terápiás vegyületek és készítmények szociális zavarok és szerhasználati zavarok kezelésére
IL268693B (en) Compounds for the treatment of glycogen storage disorders
ME03351B (fr) Composé stéroïde destiné à être utilisé dans le traitement de l&#39;encéphalopathie hépatique
EP3848022C0 (fr) Agent thérapeutique pour utilisation dans le traitement d&#39;infections
HRP20191121T1 (hr) Tretman multiple skleroze
EP3430400A4 (fr) Schémas posologiques pour le traitement d&#39;infections fongiques
EP3630080A4 (fr) Utilisation d&#39;inhibiteurs de ezh2 pour le traitement du cancer
MA39927A (fr) Inhibiteurs de glyt1 pour le traitement de troubles hématologiques
EP3813870C0 (fr) Inhibiteur de ccr5 destiné à être utilisé dans le traitement du cancer
MA39833A (fr) Nouvelle utilisation du n,n-bis-2-mercaptoéthyl isophtalamide